Franklin P. Spriggs

Learn More
Several detection platforms are available for ligand binding assays (LBA), each claiming superiority in sensitivity and dynamic range. However, little information exists in the literature directly comparing the various LBA platforms for quantitation. We have tested four common platforms to evaluate and compare the interchangeability of detection platforms(More)
BACKGROUND Ligand-binding assays are a tool used for the quantification of antibody therapies. When assay format changes are required during the drug development process it is advisable to assess these formats ensuring the resulting data can be compared. In this article, we outline the method and results obtained comparing an anti-idiotype capture and a(More)
The pharmacokinetics of an antibody (huA1)-drug (auristatin microtubule disrupting MMAF) conjugate, targeting 5T4-expressing cells, were characterized during the discovery and development phases in female nu/nu mice and cynomolgus monkeys after a single dose and in S-D rats and cynomolgus monkeys from multidose toxicity studies. Plasma/serum samples were(More)
BACKGROUND Matrix effects pose a constant challenge in developing robust ligand-binding assays to be validated for use in nonclinical and clinical study support. When notable matrix effects of any kind are present, it can render an otherwise sound method ineffective. We present two case studies detailing the mitigation of observed matrix effects. METHOD A(More)
The 10th annual Applied Pharmaceutical Analysis (APA) conference was held from 8th to 10th September in Cambridge, MA, USA. This year's APA conference focused on three different 'workshops' over the 3 days: Regulated Bioanalysis, Biotransformation, and Discovery. There was a great amount of information discussed by a variety of experts over the 3 days. This(More)
  • 1